132 related articles for article (PubMed ID: 17577097)
1. Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms.
Baker JE; Kozik D; Hsu AK; Fu X; Tweddell JS; Gross GJ
J Cardiovasc Pharmacol; 2007 Jun; 49(6):337-45. PubMed ID: 17577097
[TBL] [Abstract][Full Text] [Related]
2. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts.
Strande JL; Hsu A; Su J; Fu X; Gross GJ; Baker JE
Basic Res Cardiol; 2007 Jul; 102(4):350-8. PubMed ID: 17468933
[TBL] [Abstract][Full Text] [Related]
3. Activation of p38 mitogen-activated protein kinase abolishes insulin-mediated myocardial protection against ischemia-reperfusion injury.
Chai W; Wu Y; Li G; Cao W; Yang Z; Liu Z
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E183-9. PubMed ID: 18003719
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways.
Rafiee P; Shi Y; Su J; Pritchard KA; Tweddell JS; Baker JE
Basic Res Cardiol; 2005 May; 100(3):187-97. PubMed ID: 15611843
[TBL] [Abstract][Full Text] [Related]
5. GSK3beta inhibition and K(ATP) channel opening mediate acute opioid-induced cardioprotection at reperfusion.
Gross ER; Hsu AK; Gross GJ
Basic Res Cardiol; 2007 Jul; 102(4):341-9. PubMed ID: 17450314
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts.
Hirata A; Minamino T; Asanuma H; Sanada S; Fujita M; Tsukamoto O; Wakeno M; Myoishi M; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Tomoike H; Hori M; Kitakaze M
Cardiovasc Drugs Ther; 2005 Jan; 19(1):33-40. PubMed ID: 15883754
[TBL] [Abstract][Full Text] [Related]
7. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism.
Xu X; Cao Z; Cao B; Li J; Guo L; Que L; Ha T; Chen Q; Li C; Li Y
Surgery; 2009 Sep; 146(3):506-14. PubMed ID: 19715808
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury.
Cai Z; Semenza GL
Circulation; 2004 May; 109(17):2050-3. PubMed ID: 15117842
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling.
Das S; Tosaki A; Bagchi D; Maulik N; Das DK
J Pharmacol Exp Ther; 2006 Jun; 317(3):980-8. PubMed ID: 16525036
[TBL] [Abstract][Full Text] [Related]
10. Sevoflurane postconditioning protects isolated rat hearts against ischemia-reperfusion injury.
Yao YT; Fang NX; Shi CX; Li LH
Chin Med J (Engl); 2010 May; 123(10):1320-8. PubMed ID: 20529589
[TBL] [Abstract][Full Text] [Related]
11. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
[TBL] [Abstract][Full Text] [Related]
12. Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart.
Gao E; Boucher M; Chuprun JK; Zhou RH; Eckhart AD; Koch WJ
Am J Physiol Heart Circ Physiol; 2007 Jul; 293(1):H60-8. PubMed ID: 17384131
[TBL] [Abstract][Full Text] [Related]
13. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury.
Simpkin JC; Yellon DM; Davidson SM; Lim SY; Wynne AM; Smith CC
Basic Res Cardiol; 2007 Nov; 102(6):518-28. PubMed ID: 17694254
[TBL] [Abstract][Full Text] [Related]
14. Parstatin: a cryptic peptide involved in cardioprotection after ischaemia and reperfusion injury.
Strande JL; Widlansky ME; Tsopanoglou NE; Su J; Wang J; Hsu A; Routhu KV; Baker JE
Cardiovasc Res; 2009 Jul; 83(2):325-34. PubMed ID: 19380418
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion.
Liu X; Xie W; Liu P; Duan M; Jia Z; Li W; Xu J
Life Sci; 2006 Apr; 78(19):2255-64. PubMed ID: 16336978
[TBL] [Abstract][Full Text] [Related]
16. Postconditioning with glucagon like peptide-2 reduces ischemia/reperfusion injury in isolated rat hearts: role of survival kinases and mitochondrial KATP channels.
Penna C; Pasqua T; Perrelli MG; Pagliaro P; Cerra MC; Angelone T
Basic Res Cardiol; 2012 Jul; 107(4):272. PubMed ID: 22699364
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo.
Bullard AJ; Govewalla P; Yellon DM
Basic Res Cardiol; 2005 Sep; 100(5):397-403. PubMed ID: 15944807
[TBL] [Abstract][Full Text] [Related]
18. The tyrosine phosphatase inhibitor bis(maltolato)oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels.
Liem DA; Gho CC; Gho BC; Kazim S; Manintveld OC; Verdouw PD; Duncker DJ
J Pharmacol Exp Ther; 2004 Jun; 309(3):1256-62. PubMed ID: 14993257
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotection of interleukin-2 is mediated via kappa-opioid receptors.
Cao CM; Xia Q; Tu J; Chen M; Wu S; Wong TM
J Pharmacol Exp Ther; 2004 May; 309(2):560-7. PubMed ID: 14747612
[TBL] [Abstract][Full Text] [Related]
20. A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model.
Nagaoka K; Matoba T; Mao Y; Nakano Y; Ikeda G; Egusa S; Tokutome M; Nagahama R; Nakano K; Sunagawa K; Egashira K
PLoS One; 2015; 10(7):e0132451. PubMed ID: 26167913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
